VX-770 (Ivacaftor) is a potentiator of CFTR, which targeting G551D-CFTR and F508del-CFTR with EC50 of 100 nM and 25 nM, respectively. VX-770 (Ivacaftor) inhibits excessive ENaC-mediated Na+ and fluid absorption with an IC50 of 43 nM, and decreases the amiloride response, resulting in an increase in the surface fluid and cilia beat frequency (CBF) in G551D/F508del HBE. VX-770 (Ivacaftor) is the first potent and orally available CFTR potentiator to enter human clinical trials. It showed that VX-770 (Ivacaftor) was associated with within-subject improvements in CFTR and lung function. These findings provide support for further studies of pharmacologic potentiation of CFTR as a means to treat cystic fibrosis.
|Source||Physiology University of Toronto (2015). Figure 21. VX-770 (AbMole BioScience, Cedarlane, Burlington, Canada)|
|Cell Lines||C57BL/6 WT mice|
|Incubation Time||30 min|
|Results||Since CFTR(inh)-172 results in the inhibition of proper CFTR gating leading to an elevated myogenic vasoconstriction, treatment with potentiator VX-770 might also potentiate CFTR’s capacity to transport S1P and, therefore, compensate for part of the lost CFTR.|
|Preparation method||Iodide Flux Assay—Proteoliposomes were reconstituted in the presence of 75 mM KI. The external iodide was exchanged for 75 mM potassium glutamate by gel filtration chromatography. External iodide concentrations were monitored continuously using an iodide-selective electrode (Lazar Research Laboratories, Los Angeles, CA) interfaced to the Digidata 1320A data acquisi ion system and controlled by Clampex 8 software (Axon Instruments, Sunnyvale, CA), as described previously (17, 18).|
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.
|Solubility||DMSO ≥75 mg/mL|
Cystic fibrosis transmembrane conductance regulator (CFTR) potentiator VX-770 (ivacaftor) opens the defective channel gate of mutant CFTR in a phosphorylation-dependent but ATP-independent manner.
Eckford PD, et al. J Biol Chem. 2012 Oct 26;287(44):36639-49. PMID: 22942289.
|Related CFTR Products|
GLPG1837 (ABBV-974) is a novel CFTR potentiator, with EC50s of 3 nM and 339 nM for F508del and G551D CFTR, respectively.
PPQ-102 is a potent CFTR inhibitor which can completely inhibited CFTR chloride current with IC 50 approximately 90 nM.
VX-661 is a second F508del CFTR corrector and is believed to help CFTR protein reach the cell surface.
IOWH032 is a synthetic CFTR inhibitor with IC50 of 1.01 μM in CHO-CFTR cell based assays. Phase 1/2.
CFTRinh-172 is a voltage-independent, selective CFTR inhibitor with Ki of 300 nM, showing no effects on MDR1, ATP-sensitive K+ channels, or a series of other transporters.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2017 AbMole BioScience. All Rights Reserved.